ATM Function During V(D)J Recombination
V(D)J 重组期间的 ATM 功能
基本信息
- 批准号:10307563
- 负责人:
- 金额:$ 37.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-02 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:ATM functionAntigen ReceptorsAvidityB-LymphocytesBindingCellsChromatinChromosomal translocationChromosome DeletionCodeComplement Factor BDNADNA DamageDNA Double Strand BreakDNA RepairDefectDouble Strand Break RepairEvolutionG22P1 geneGenesGenomeGenomic InstabilityGoalsGuide RNAHourHumanIndividualInfectionJ segment geneLIG4 geneLeadLymphocyte antigenMalignant NeoplasmsMediatingMusNonhomologous DNA End JoiningOncogenicPathway interactionsProteinsReactionReceptor GeneRegulationResolutionRetroviridae InfectionsRoleSignal TransductionT-LymphocyteTestingTissuesV(D)J RecombinationXRCC4 geneXRCC5 geneartemisbasecancer cellcell typeendonucleasefactor Afactor Cgenome integritylymphoid neoplasmmetaplastic cell transformationnovelpreventprotein functionrepairedresponsescreeningseal
项目摘要
Abstract
Lymphocyte antigen receptor gene assembly occurs through the V(D)J recombination reaction. This reaction
is initiated when the RAG-1 and RAG-2 proteins, which form the RAG endonuclease, introduces two DNA
double strand breaks (DSBs) at the border of two recombining gene segments and their associated V, D or J
gene segments. This results in the formation of a coding end and a signal end at each DSB. The coding ends
must be joined to form a coding join and the signal ends joined to form a signal join. Also, as a single
individual can make up to 60,000,000 RAG DSBs in an hour in developing B and T cells, pathways must be in
place to prevent un-repaired RAG DSBs from being aberrantly repaired, forming potentially transforming
chromosomal deletions and translocations. The non-homologous end-joining pathway of DNA DSB repair
joins DNA DSBs generated by RAG cleavage. NHEJ relies on four core NHEJ factors, XRCC4, DNA Ligase
IV, Ku70 and Ku80. However, there are other non-core NHEJ factors that function during the NHEJ-mediated
repair of RAG DSBs. For example, coding join formation relies on the ncNHEJ factor, Artemis, which is
endonuclease that opens the hairpin-sealed coding ends generated by RAG cleavage. Artemis is not required
for joining signal ends. In addition, there are other ncNHEJ factors that are not themselves required for RAG
DSB repair, but that likely effect the efficiency of RAG DSB repair or function to prevent aberrant repair of RAG
DSBs that are not joined efficiently. Identifying ncNHEJ factors has been challenging given that their deletion
does not often lead to a demonstrable defect in the repair of RAG DSBs. However, recent studies have
established that combined deficiencies of putative ncNHEJ factors can lead to demonstrable defects in RAG
DSBs repair. This has been a powerful candidate-based approach for identifying several ncNHEJ factors and
elucidating their mechanisms of action in NHEJ-mediated DSB repair and DNA damage responses (DDR).
Indeed, using this type of approach, we have identified a novel ncNHEJ protein, modulator of retroviral
infection (MRI), that binds through its N- and C-terminus to a functionally diverse set of NHEJ and DDR
proteins. We believe that MRI functions as an adaptor during several steps of NHEJ-mediated repair of RAG
DSBs and during the DDR to RAG DSBs. Here we propose a novel unbiased screening approach to identify
the network of ncNHEJ factors that function during RAG DSB repair. We also propose to elucidate the
mechanisms of action of these ncNHEJ factors focusing initially on the novel ncNHEJ factor, MRI, that we
recently discovered that functions in RAG DSB repair. These studies will reveal novel activities required for the
NHEJ-mediated repair of RAG DSBs. These activities will likely be generally relevant to NHEJ in other tissues
and to our understanding to DNA repair defects that lead to genome evolution in cancers.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARRY P SLECKMAN其他文献
BARRY P SLECKMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARRY P SLECKMAN', 18)}}的其他基金
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 37.13万 - 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 37.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 37.13万 - 项目类别:
Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 37.13万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
9922602 - 财政年份:2020
- 资助金额:
$ 37.13万 - 项目类别: